Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Double anti-B8571-ADC
- Development stage
- Preclinical
- Lead developer
- Nanolattix
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Double anti-B8571-ADC is a preclinical bispecific antibody-drug conjugate (ADC) being developed by Nanolattix for the treatment of various solid tumors, including lung, stomach, and breast cancers. As a bispecific ADC, it is engineered to recognize two different antigens or epitopes, potentially increasing tumor specificity and overcoming resistance mechanisms associated with single-target therapies. Upon binding to its targets, the conjugate is internalized, leading to the intracellular release of a cytotoxic payload that induces apoptosis in the malignant cells.
- Other names
- Double anti-B8571
Beyond the preview
Go deeper on Double anti-B8571-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Double anti-B8571-ADC.